



Focus on CD30+ malignancies

14<sup>TH</sup> SEPTEMBER 2017 | 1900-2130

Capri Club Lounge, Level 32, Capri by Fraser Hotel Residences,

Bangsar South City, Kuala Lumpur

Moderator: Dr Alan Teh Speaker: Dr Anna Sureda

## **PROGRAMME**

1900 • Registration

1930 • Introduction

1940 • The era of targeted therapy: Brentuximab vedotin vs Transplantation

2020 • Q&A

2030 • Clinical case discussion\*

2130 • End

\*Dinner will be served

RSVP: 1ST SEPTEMBER 2017 Sow Youn: +603 7953 3121 Email: Sow-Youn.Tan@takeda.com

JOINTLY ORGANIZED BY:





## **MODERATOR**



Dr Alan Teh Consultant Haematologist - Subang Jaya Medical Centre

Dr Alan Teh graduated from the University of Malaya in 1983. He trained in Internal Medicine, Clinical Haematology and Bone marrow transplantation. He served as lecturer and Associate Professor at the University of Malaya Medical Centre from 1988 until 1999. Since 1999 he has been practicing at the Subang Jaya Medical Centre. His interests lie in Malignant Haematology, particularly multiple myeloma, hodgkin lymphoma, acute and chronic leukaemias and haematopoietic stem cell transplantation. He is currently the serving President of the Malaysian Society of Haematology.

## **SPEAKER**




Dr Anna Sureda Head of Department, Haematology Department, Institut Català d'Oncologia – Hospital Duran I Reynals, Barcelona, Spain

Anna Sureda, (MD, PhD) graduated with a degree in Medicine from the Autonomous University of Madrid in 1986 and completed her residency in Haematology at the Hospital Ramón y Cajal of Madrid in 1990. In January/1991 she started working in the Clinical Haematology Division of the Department of Haematology at Hospital de la Santa Creu i Sant Pau in Barcelona where she was appointed Head of the Outpatient Department in 2002. In January 2011, Anna Sureda moved to Cambridge University Hospital in Cambridge, UK, Addenbrookes Hospital, where she was appointed Senior Consultant in Lymphomas and Stem Cell Transplantation. In January 2013, she moved back to Barcelona where she was appointed Head of the Haematology Department of Institut Català d'Oncologia – Hospital Duran I Reynals in June 2015. She was a Visiting Physician at the University of Heidelberg, Germany in 1990 for four months and at the Fred Hutchinson Cancer Research Center of Seattle in 1993 for another period of four months

Anna Sureda has focused her career on clinical investigations into the treatment of Hodgkin's lymphoma, non-Hodgkin's lymphoma and multiple myeloma patients evaluating novel therapies such as immunotherapy combined with stem-cell transplantation. Throughout the course of her investigations she has participated in many phase II and III clinical trials for lymphoma patients. As a result of part of her clinical investigations, she achieved her PhD with the work entitled "Autologous Stem Cell Transplantation in Patients with Hodgkin's Lymphoma" in June/2008. Dr. Sureda has been an active member of the Spanish Cooperative Group of Lymphomas and Haematopoietic Stem Cell Transplantation (GELTAMO) since 1993 and during her stay in UK she was elected active member of the NCRN Lymphoma Study Group. In April/2004 she was appointed Chairperson of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Since then, her main focus of interest has been the analysis of the results and prognostic factors of autologous and allogeneic stem cell transplantation in lymphoid malignancies. After stepping down as chairperson of the Lymphoma Working Party Anna Sureda was elected Secretary of the EBMT, her current position in this organization until April 2016.

Anna Sureda is a regular reviewer for the journals Blood, Annals of Oncology, Bone Marrow Transplantation, The Hematology Journal, The European Journal of Hematology and Annals of Hematology and has been co-authored more than 250 peer-reviewed journal articles



JOINTLY ORGANIZED BY:



